OncLive TV

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.

Sarah Rutherford, MD, discusses the importance of including patients with double-hit lymphoma in clinical trials.

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

Jennifer Woyach, MD, discusses the safety profiles of BTK inhibitors in patients with chronic lymphocytic leukemia.

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

Naval G. Daver, MD, discusses the mechanism of action of the investigational CD47-directed antibody magrolimab in acute myeloid leukemia and myelodysplastic syndrome.

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.

Andrei Gafita, MD, discusses sequencing lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Jorge E. Cortes, MD, discusses the benefits of ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms.

Sagar Lonial, MD, FACP, discusses some of the remaining challenges to address in the multiple myeloma space.

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Shilpa Gupta, MD, discusses the potential utility of neoadjuvant versus adjuvant immunotherapy in urothelial carcinoma.

Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the rationale for concurrent intrathecal and intravenous nivolumab in patients with metastatic melanoma who have leptomeningeal disease.

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.